Outcomes at least 90 days since onset of myocarditis after mRNA COVID-19 vaccination in adolescents and young adults in the USA: a follow-up surveillance studyIan Kracalik, Jacek M. Mazurek, Maleeka Glover et al.|The Lancet Child & Adolescent Health|2022Cited by 78
Cardiac manifestations and outcomes of COVID-19 vaccine-associated myocarditis in the young in the USA: longitudinal results from the Myocarditis After COVID Vaccination (MACiV) multicenter studySupriya S Jain, Andrew L. Cheng, Michael Brumund et al.|EClinicalMedicine|2024Cited by 28
Quality of Life and Exercise Capacity in Early Stage and Subclinical Hypertrophic Cardiomyopathy: A Secondary Analysis of the VANISH TrialCatherine G. Ireland, Carolyn Y. Ho, Charles E. Canter et al.|Circulation Heart Failure|2024Cited by 6
Design and implementation of multicenter pediatric and congenital studies with cardiovascular magnetic resonance: Big data in smaller bodiesMichael P. DiLorenzo, Heynric B. Grotenhuis, Kuberan Pushparajah et al.|Journal of Cardiovascular Magnetic Resonance|2024Cited by 5
Proteomic Analysis of Valsartan for Attenuating Disease Evolution in Early Sarcomeric Hypertrophic Cardiomyopathy (VANISH) Clinical TrialConstantin‐Cristian Topriceanu, Carolyn Y. Ho, Steven D. Colan et al.|Circulation Heart Failure|2025Cited by 3